Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Nucynta CR | Tapentadol | Pain, moderate to moderately severe | Do not list | Complete | ||
Zenhale (inhalation aerosol) | Mometasone furoate and formoterol | Asthma | Do not list | Complete | ||
BuTrans | Buprenorphine transdermal patch | Pain, moderate intensity persistent pain | Do not list | Complete | ||
Daxas | Roflumilast | Chronic obstructive pulmonary disease | Do not list | Complete | ||
Cayston | Aztreonam for inhalation solution | Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections | List with clinical criteria and/or conditions | Complete | ||
Restasis ophthalmic emulsion | Cyclosporine | Dry eye disease | Do not list | Complete | ||
Celsentri | Maraviroc | HIV infection | Do not list | Complete | ||
Abilify | Aripiprazole | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
Pradaxa | Dabigatran etexilate | Atrial fibrillation prevention of stroke and systemic embolism | List with clinical criteria and/or conditions | Complete | ||
Invega Sustenna | Paliperidone palmitate | Schizophrenia | Do not list | Complete |